These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9041207)

  • 21. [Appropriate iron supplementation in renal anemia treatment].
    Suzuki M
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():566-8. PubMed ID: 15250370
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation and treatment of iron deficiency in patients with kidney disease.
    Bickford AK
    Nutr Clin Care; 2002; 5(5):225-30. PubMed ID: 12455224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indices of iron status in patients treated by chronic haemodialysis.
    Zupan IP; Varl J; Kovac D; Cernelc P; Mlakar U; Andoljsek D; Pretnar J; Zver S; Modic M
    Pflugers Arch; 2001; 442(6 Suppl 1):R202-3. PubMed ID: 11678340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of renal anemia with iron in hemodialysis patients in General Hospital Bjelovar].
    Lovcić V; Vujić J; Basić-Jukić N; Janković RI; Kurtović I; Dzapo M; Lovcić P
    Acta Med Croatica; 2011 Oct; 65 Suppl 3():45-8. PubMed ID: 23120815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iron requirements in hemodialysis.
    Sargent JA; Acchiardo SR
    Blood Purif; 2004; 22(1):112-23. PubMed ID: 14732819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin.
    Markowitz GS; Kahn GA; Feingold RE; Coco M; Lynn RI
    Clin Nephrol; 1997 Jul; 48(1):34-40. PubMed ID: 9247776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure.
    Ahluwalia N; Skikne BS; Savin V; Chonko A
    Am J Kidney Dis; 1997 Oct; 30(4):532-41. PubMed ID: 9328369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indices of iron status in continuous ambulatory peritoneal dialysis patients.
    Domrongkitchaiporn S; Jirakranont B; Atamasrikul K; Ungkanont A; Bunyaratvej A
    Am J Kidney Dis; 1999 Jul; 34(1):29-35. PubMed ID: 10401012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble transferrin receptor and sTfR-F index for assessing concurrent iron deficiency in patients with chronic renal failure.
    Choi JW
    Ann Hematol; 2008 Jul; 87(7):575-6. PubMed ID: 18317758
    [No Abstract]   [Full Text] [Related]  

  • 31. Soluble transferrin receptor is correlated with erythropoietin sensitivity in dialysis patients.
    Daschner M; Mehls O; Schaefer F
    Clin Nephrol; 1999 Oct; 52(4):246-52. PubMed ID: 10543327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous iron supplementation in end-stage renal disease patients.
    Matzke GR
    Am J Kidney Dis; 1999 Mar; 33(3):595-7. PubMed ID: 10070926
    [No Abstract]   [Full Text] [Related]  

  • 34. National perspective on iron therapy as a clinical performance measure for maintenance hemodialysis patients.
    Owen WF; Szczech L; Johnson C; Frankenfield D
    Am J Kidney Dis; 1999 Oct; 34(4 Suppl 2):S5-S11. PubMed ID: 10516369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefits of early utilization of intravenous iron.
    Vogel S
    Nephrol Nurs J; 2000 Feb; 27(1):61-5. PubMed ID: 10852693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Individual differences in the efficacy of Recormon in patients with terminal kidney failure. The role of iron deficiency].
    Nikolaev AIu; Klepikov PV; Lashutin SV; Kondakhchan MA; Rogov VA; Trofimova EI
    Ter Arkh; 1993; 65(6):45-8. PubMed ID: 8378849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy.
    Tarng DC; Huang TP; Chen TW
    Am J Nephrol; 1997; 17(2):158-64. PubMed ID: 9096447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral iron absorption in hemodialysis patients treated with erythropoietin.
    Donnelly SM; Posen GA; Ali MA
    Clin Invest Med; 1991 Aug; 14(4):271-6. PubMed ID: 1782724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study.
    Ahsan N
    J Am Soc Nephrol; 1998 Apr; 9(4):664-8. PubMed ID: 9555669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transferrin receptor assay and zinc protoporphyrin as markers of iron-deficient erythropoiesis in end-stage renal disease patients.
    Baldus M; Walter H; Thies K; Anders C; Stein M; Hellstern P; Brass H
    Clin Nephrol; 1998 Mar; 49(3):186-92. PubMed ID: 9543601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.